guest ::
| Home > Publications Database > c-Jun inhibition mitigates chemotherapy-induced neurotoxicity in iPSC-derived sensory neurons. > print |
| Home > Publications Database > c-Jun inhibition mitigates chemotherapy-induced neurotoxicity in iPSC-derived sensory neurons. > print |
| 001 | 282300 | ||
| 005 | 20251218103440.0 | ||
| 024 | 7 | _ | |a 10.1038/s41420-025-02847-5 |2 doi |
| 024 | 7 | _ | |a pmid:41233356 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12615653 |2 pmc |
| 037 | _ | _ | |a DZNE-2025-01270 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Hew, Lois |0 0000-0002-0183-8177 |b 0 |
| 245 | _ | _ | |a c-Jun inhibition mitigates chemotherapy-induced neurotoxicity in iPSC-derived sensory neurons. |
| 260 | _ | _ | |a London |c 2025 |b Nature Publishing Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1765965035_5347 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Chemotherapy-induced peripheral neuropathy (CIPN) affects up to two-thirds of cancer patients undergoing cytotoxic chemotherapy. Here, we used human iPSC-derived sensory neurons (iPSC-DSN) to model CIPN in vitro. Administration of various chemotherapeutic agents (i.e., paclitaxel, vincristine, bortezomib and cisplatin) at clinically applicable concentrations resulted in reduced cell viability, axonal degeneration, electrophysiological dysfunction and increased levels of phosphorylated c-Jun in iPSC-DSN. Transcriptomic analyses revealed that the upregulation of c-Jun strongly correlated with the expression of genes of neuronal injury, apoptosis and inflammatory signatures. To test whether c-Jun plays a central role in the development of CIPN, we applied the small molecule inhibitor of the Jun N-terminal kinase, SP600125, to iPSC-DSN treated with neurotoxic chemotherapy. c-Jun inhibition prevented chemotherapy-induced neurotoxicity by preserving cell viability, axonal integrity and electrophysiological function of iPSC-DSN. These findings identify c-Jun as a key mediator of CIPN pathophysiology across multiple drug types and present preclinical evidence that c-Jun inhibition is an attractive therapeutic target to prevent CIPN. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 700 | 1 | _ | |a Maierhof, Smilla K |b 1 |
| 700 | 1 | _ | |a Ivanov, Andranik |b 2 |
| 700 | 1 | _ | |a Beule, Dieter |b 3 |
| 700 | 1 | _ | |a Fernandez Vallone, Valeria |b 4 |
| 700 | 1 | _ | |a Stachelscheid, Harald |0 0000-0002-9283-4605 |b 5 |
| 700 | 1 | _ | |a Frahm, Silke |0 0000-0001-5645-2557 |b 6 |
| 700 | 1 | _ | |a Telugu, Narasimha Swamy |b 7 |
| 700 | 1 | _ | |a Endres, Matthias |0 P:(DE-2719)2811033 |b 8 |e Last author |
| 700 | 1 | _ | |a Boehmerle, Wolfgang |0 0000-0001-7195-3894 |b 9 |
| 700 | 1 | _ | |a Huehnchen, Petra |0 0000-0002-6825-7270 |b 10 |
| 700 | 1 | _ | |a Schinke, Christian |0 0000-0003-0199-9672 |b 11 |
| 773 | _ | _ | |a 10.1038/s41420-025-02847-5 |g Vol. 11, no. 1, p. 529 |0 PERI:(DE-600)2842546-7 |n 1 |p 529 |t Cell death discovery |v 11 |y 2025 |x 2058-7716 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/282300/files/DZNE-2025-01270%20SUP.zip |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/282300/files/DZNE-2025-01270.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/282300/files/DZNE-2025-01270.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:282300 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2811033 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-21 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-04-10T15:36:08Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-04-10T15:36:08Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-21 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-21 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2024-04-10T15:36:08Z |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-21 |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Interdisciplinary Dementia Research |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|